Pengo, Marta
Alberici, Antonella
Libri, Ilenia
Benussi, Alberto
Gadola, Yasmine
Ashton, Nicholas J.
Zetterberg, Henrik
Blennow, Kaj
Borroni, Barbara http://orcid.org/0000-0001-9340-9814
Funding for this research was provided by:
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Università degli Studi di Brescia
Article History
Received: 11 May 2022
Accepted: 28 May 2022
First Online: 8 June 2022
Declarations
:
: The authors report no disclosures relevant to the manuscript.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
: A written Informed consent was obtained from each subject. The work conforms to the Helsinki Declaration and was approved by the ethics committee of our hospital.